Detalhe da pesquisa
1.
Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): patient-reported outcomes from a randomised, open-label, multicentre, phase 3 trial.
Lancet Oncol
; 25(5): 614-625, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38697155
2.
Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial.
Lancet
; 401(10390): 1773-1785, 2023 05 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-37086745
3.
Association of Neutrophil-to-Lymphocyte Ratio and Absolute Lymphocyte Count With Clinical Outcomes in Advanced Breast Cancer in the MONARCH 2 Trial.
Oncologist
; 29(3): e319-e329, 2024 Mar 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-37971418
4.
Targeting Sphingosine-1-Phosphate Signaling in Breast Cancer.
Int J Mol Sci
; 25(6)2024 Mar 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38542328
5.
Intratumoral Tumor Infiltrating Lymphocytes (TILs) are Associated With Cell Proliferation and Better Survival But Not Always With Chemotherapy Response in Breast Cancer.
Ann Surg
; 278(4): 587-597, 2023 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37318852
6.
Baseline interleukin-6 is a prognostic factor for patients with metastatic breast cancer treated with eribulin.
Breast Cancer Res Treat
; 202(3): 575-583, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-37733188
7.
Early assessment of tumor response using 18F-FDG PET/CT after one cycle of systemic therapy in patients with recurrent and metastatic breast cancer.
Hell J Nucl Med
; 25(2): 155-162, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35913863
8.
Significant association between high serum CCL5 levels and better disease-free survival of patients with early breast cancer.
Cancer Sci
; 111(1): 209-218, 2020 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-31724785
9.
Harmonized pretreatment quantitative volume-based 18F-FDG PET/CT parameters for stage IV breast cancer prognosis. Multicenter study in Japan.
Hell J Nucl Med
; 23(3): 272-289, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-33367302
10.
Participants in a randomized controlled trial had longer overall survival than non-participants: a prospective cohort study.
Breast Cancer Res Treat
; 176(3): 631-635, 2019 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-31115845
11.
Significance of Metabolic Tumor Volume at Baseline and Reduction of Mean Standardized Uptake Value in 18F-FDG-PET/CT Imaging for Predicting Pathological Complete Response in Breast Cancers Treated with Preoperative Chemotherapy.
Ann Surg Oncol
; 26(7): 2175-2183, 2019 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-30941655
12.
Prognostic value of 18F-FDG PET/CT prior to breast cancer treatment. Comparison with magnetic resonance spectroscopy and diffusion weighted imaging.
Hell J Nucl Med
; 22(1): 25-35, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-30843007
13.
Abundant tumor infiltrating lymphocytes after primary systemic chemotherapy predicts poor prognosis in estrogen receptor-positive/HER2-negative breast cancers.
Breast Cancer Res Treat
; 168(1): 135-145, 2018 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-29168063
14.
Response to neoadjuvant chemotherapy for breast cancer judged by PERCIST - multicenter study in Japan.
Eur J Nucl Med Mol Imaging
; 45(10): 1661-1671, 2018 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-29754160
15.
Predictive impact of absolute lymphocyte counts for progression-free survival in human epidermal growth factor receptor 2-positive advanced breast cancer treated with pertuzumab and trastuzumab plus eribulin or nab-paclitaxel.
BMC Cancer
; 18(1): 982, 2018 Oct 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-30326862
16.
High levels of serum CA15-3 and residual invasive tumor size are associated with poor prognosis for breast cancer patients with non-pathological complete response after neoadjuvant chemotherapy.
J Surg Oncol
; 118(1): 228-237, 2018 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-29936704
17.
Independent prognostic impact of preoperative serum carcinoembryonic antigen and cancer antigen 15-3 levels for early breast cancer subtypes.
World J Surg Oncol
; 16(1): 26, 2018 Feb 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-29433529
18.
Assessment of tumor response to neoadjuvant chemotherapy in patients with breast cancer using MRI and FDG-PET/CT-RECIST 1.1 vs. PERCIST 1.0.
Nagoya J Med Sci
; 80(2): 183-197, 2018 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-29915436
19.
HP1 regulates the localization of FANCJ at sites of DNA double-strand breaks.
Cancer Sci
; 107(10): 1406-1415, 2016 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-27399284
20.
Impact of biomarker changes during neoadjuvant chemotherapy for clinical response in patients with residual breast cancers.
Int J Clin Oncol
; 21(2): 254-261, 2016 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-26338270